Frank Frissora

Title: Frank Frissora: Innovator in Therapeutic Agents for Lymphoid Malignancies

Introduction

Frank Frissora is a notable inventor based in Columbus, OH (US). He has made significant contributions to the field of medicine, particularly in the treatment of lymphoid malignancies. His innovative work has led to the development of therapeutic agents that aim to improve patient outcomes in various types of blood cancers.

Latest Patents

Frank Frissora holds a patent for "Therapeutic agents for the treatment of lymphoid malignancies." This patent outlines methods for the treatment and prevention of conditions such as acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), B-cell lymphoma, acute myeloid leukemia (AML), and mantle cell lymphoma (MCL). The methods described in the patent involve the administration of a therapeutically effective amount of FTY720 (2-Amino-2-[2-(4-octylphenyl)ethyl]propane 1,3-diol hydrochloride) or its derivatives, pharmaceutically acceptable salts, or prodrugs to patients.

Career Highlights

Frank Frissora is affiliated with The Ohio State University, where he continues to engage in research and development in the field of oncology. His work has been instrumental in advancing therapeutic strategies for patients suffering from lymphoid malignancies.

Collaborations

Frank has collaborated with esteemed colleagues such as John C Byrd and Danilo Perrotti, contributing to a rich environment of research and innovation.

Conclusion

Frank Frissora's contributions to the field of therapeutic agents for lymphoid malignancies highlight his dedication to improving cancer treatment. His innovative approaches and collaborations with other experts underscore the importance of teamwork in advancing medical science.